Good afternoon and welcome to Markets Desk.
The biopharma space is under pressure today after Novartis reported a failed trial for its Lp-a lowering cholesterol drug. The setback triggered a broad selloff across drugmakers who have placed similar bets on that cardiovascular pathway, raising fresh questions about whether reducing Lp-a levels actually translates into fewer fatal heart events for patients.
Shifting to semiconductors, Qualcomm is surging more than ten percent after announcing a data center infrastructure deal with Amazon. The company has largely missed the chip sector's rally this year as investors stayed focused on Nvidia's dominance in AI, but this partnership signals Qualcomm is making a serious push into the data center market, giving investors the catalyst they have been waiting for.
And staying in the chip space, that Qualcomm move is worth watching in the broader context of the AI infrastructure buildout. Amazon's decision to diversify its chip partnerships suggests the hyperscalers are no longer content concentrating that supply chain risk in a single vendor, which could open meaningful opportunities for challengers across the semiconductor landscape.
That's the tape. Markets Desk, signing off the floor.
